Regeneron Pharmaceuticals Inc

More

• Regeneron, Sanofi asthma drug seen as potential game changer Tuesday, 21 May 2013 | 8:14 AM ET

  May 21- A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said on Tuesday.

• Jim Cramer’s 5 Investing Sweet Spots Tuesday, 14 May 2013 | 6:00 PM ET

  

  Following are 5 themes and related stock ideas that Jim Cramer likes right here and right now.

• REUTERS SUMMIT-Biotech firms evolve from targets to acquirers Tuesday, 7 May 2013 | 2:55 PM ET

  *Bankers expect steady flow of $1 bln to $5 bln pharma deals. The stock valuations of companies like Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Celgene Corp and Biogen Idec Inc have skyrocketed in the past year or two alone, making it difficult for large pharmaceutical companies to buy them and leaving a trail of dead deals.

• FEATURE-Fast climbing biotech Regeneron still has room to grow Tuesday, 7 May 2013 | 11:00 AM ET

  *Risks include high valuation, competitive threats By Ransdell Pierson. TARRYTOWN, N.Y., May 7- Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle," "The Legend of Sleepy Hollow," and other creations of hometown author Washington Irving.

• FEATURE-Fast climbing biotech Regeneron still has room to grow Tuesday, 7 May 2013 | 10:59 AM ET

  *Shares jump five-fold in two years, market value $26 bln. TARRYTOWN, N.Y., May 7- Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle," "The Legend of Sleepy Hollow," and other creations of hometown author Washington Irving.

• RESEARCH ALERT-Regeneron Pharmaceuticals : RBC raises price target Monday, 6 May 2013 | 8:16 AM ET

  May 6- Regeneron Pharmaceuticals Inc:. For a summary of rating and price target changes on U.S. companies: Reuters Eikon users, click on RCH/US Reuters 3000 Xtra users, double-click RCH/US Reuters Station users, click. 1568.

• RESEARCH ALERT-Regeneron Pharmaceuticals: Jefferies raises price target Monday, 6 May 2013 | 6:57 AM ET

  May 6- Regeneron Pharmaceuticals Inc:. *Jefferies raises price target to $247 from $179. Reuters Station users, click. 1568.

• RESEARCH ALERT-Regeneron Pharmaceuticals: Roth Capital raises price target Monday, 6 May 2013 | 6:27 AM ET

  May 6- Regeneron Pharmaceuticals Inc:. *Roth Capital raises price target to $314 from $200; rating buy. Reuters Station users, click. 1568.

• RESEARCH ALERT-Regeneron Pharmaceuticals: RBC raises price target to $286 Friday, 3 May 2013 | 3:43 PM ET

  May 3- Regeneron Pharmaceuticals Inc:. *RBC raises price target to $286 from $270; rating outperform. Reuters Station users, click. 1568.

• MARKET PULSE-LinkedIn, Arena Pharma, Radcom, Delcath, Solar stocks Friday, 3 May 2013 | 3:35 PM ET

  **RADCOM LTD, $4.05, up 53 pct. **DELCATH SYSTEMS INC, $0.43, down 45 pct. **LINKEDIN CORP, $181.69, down 10 pct.

• CORRECTED-MARKET PULSE-LinkedIn, Arena Pharma, Radcom, Delcath, YRC Worldwide Friday, 3 May 2013 | 2:02 PM ET

  **RADCOM LTD, $4.05, up 53 pct. **DELCATH SYSTEMS INC, $0.43, down 45 pct. **LINKEDIN CORP, $181.69, down 10 pct.

• MARKET PULSE-LinkedIn, Arena Pharma, Radcom, Delcath, YRC Worldwide Friday, 3 May 2013 | 1:29 PM ET

  **RADCOM LTD, $4.05, up 53 pct. **DELCATH SYSTEMS INC, $0.43, down 45 pct. **LINKEDIN CORP, $181.69, down 10 pct.

• MARKET PULSE-LinkedIn, Arena Pharma, Radcom, Chemed, Vocera, Procera Friday, 3 May 2013 | 11:27 AM ET

  **LINKEDIN CORP, $186.46, down 8 pct. **VIVUS INC, $13.28, up 3 pct. Arena said on Thursday that it pulled its application seeking approval for its anti-obesity treatment Belviq in the European Union, lowering competition for rival Vivus, whose obesity pill was recommended for European approval by regulators late last month.

• MARKET PULSE-LinkedIn, Arena Pharma, Chemed, Vocera, Procera, Zagg Friday, 3 May 2013 | 10:17 AM ET

  **LINKEDIN CORP, $186.46, down 8 pct. **VIVUS INC, $13.28, up 3 pct. Arena said on Thursday that it pulled its application seeking approval for its anti-obesity treatment Belviq in the European Union, lowering competition for rival Vivus, whose obesity pill was recommended for European approval by regulators late last month.

• MARKET PULSE-LinkedIn, Arena Pharma, Chemed, Blucora, AIG, Regeneron Friday, 3 May 2013 | 8:56 AM ET

  **LINKEDIN CORP, Thursday close $201.67, down 9 pct premarket. **VIVUS INC, Thursday close $12.95, up 4 pct premarket.

• MARKET PULSE-JP Morgan, LinkedIn, Moody's, Arena Pharma, AIG Friday, 3 May 2013 | 7:48 AM ET

  **JPMORGAN CHASE& CO, Thursday close $48.08. U.S. government investigators have found that the company had manipulated trading in the California and Michigan electricity markets, the New York Times reported. **LINKEDIN CORP, Thursday close $201.67, down 10 pct after market.

• MARKET PULSE-LinkedIn, Arena Pharma, Radcom, Chemed, Vocera, YRC Worldwide Friday, 3 May 2013 | 12:57 AM ET

  **RADCOM LTD, $4.05, up 53 pct. **LINKEDIN CORP, $181.69, down 10 pct. The U.S. Justice Department is suing the company and its hospice subsidiaries, including the biggest U.S. for-profit hospice chain, alleging false billings for Medicare hospice services.

• STOCKS NEWS EUROPE-U.S. non-farm payrolls eyed on Fri Thursday, 2 May 2013 | 10:20 AM ET

  BNP PARIBAS SA Q1 AIR FRANCE KLM SA Q1 ADIDAS AG Q1 COMPAGNIE GEOPHYSIQUE SA Q1 TELEFONICA DEUTSCHLAND AG Q1 GN STORE NORD A/S Q1 SMURFIT KAPPA GROUP PLC Q1 TDC A/S Q1 WERELDHAVE NV Q1 BELGACOM SA Q1 BOLIDEN AB Q1 CONTINENTAL AG Q1 MAPFRE SA Q1 NCC AB Q1 SKY DEUTSCHLAND Q1 VEOLIA Q1 MAJOR U.S.

• RESEARCH ALERT-Regeneron Pharmaceuticals: Credit Suisse raises target price Thursday, 2 May 2013 | 10:19 AM ET

  May 2- Regeneron Pharmaceuticals Inc:. *Credit Suisse raises target price to $275 from $187; rating outperform. Reuters Station users, click. 1568.

• RESEARCH ALERT-Regeneron Pharmaceuticals: JMP Securities raises to market outperform Thursday, 2 May 2013 | 4:38 AM ET

  May 2- Regeneron Pharmaceuticals Inc:. *JMP Securities raises to market outperform from market perform. Reuters Station users, click. 1568.